-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Meeting News
-
In Brief for May 25, 2022
5th edition of patient education book released; US FDA moves to prohibit tobacco flavoring.
-
Low-Dose CT, ctDNA May Partner for Lung Cancer Detection
Liquid biopsy tool may be useful in high-risk individuals unwilling or unable to undergo LDCT.
-
Award Lecture Highlights Tumor Evolution Through Liquid Biopsy
The UK’s Dr. Charles Swanton received the ISLB’s 2021 award for outstanding scientific contribution.
-
In Brief for February 23, 2022
TTLC 2022 gets under way. WCLC registration now open but abstract submission deadline is coming soon.
-
In Brief for February 9, 2022
TTLC goes virtual. Positive results reported for pembrolizumab. GO2 Foundation names Chief of Healthcare Delivery.
-
Keynote Addresses Lessons from SCLC Mouse Models
Experimental model systems are an indispensable part of research into SCLC. At the International Association for the Study of Lung Cancer’s 2021 Hot Topic Meeting: Small Cell Lung Cancer, keynote speaker Julien Sage, PhD, discussed the importance of these experimental models, specifically mouse models, in moving the field forward. Dr. Sage, who is the Elaine…
-
CDX Models Help Bring Personalized Treatment for SCLC a Step Closer
A growing body of research in SCLC has revealed greater phenotypic heterogeneity within this disease than previously realized. Circulating-tumor-cell-derived explant models (CDX) are providing researchers with a resource to facilitate personalization of SCLC treatment. At the International Association for the Study of Lung Cancer’s 2021 Hot Topic Meeting: Small Cell Lung Cancer, the opening keynote…
-
Preconditioning Program Shortens Postsurgical Hospital Stay for People with Lung Cancer
Reducing complications after lung cancer surgery could generate positive changes across healthcare, from better outcomes and quality of life to cost savings. Even a small decrease in incidence of postoperative complications could have meaningful results as they affect approximately 10% to 30% of those who undergo pulmonary resection and up to 50% of those treated…
-
Novel RET Inhibitors Promising in Chinese Patients with RET-fusion Positive NSCLC
The results of two studies presented at the 2021 World Conference on Lung Cancer—LIBRETTO-321 and ARROW—indicate that the selective RET inhibitors selpercatinib and pralsetinib are promising treatment options for patients in China with RET-fusion positive NSCLC. According to the studies’ discussant Shengxiang (Henry) Ren, MD, PhD, of Shanghai Pulmonary Hospital, Tongji University, Shanghai, China, both…
-
Second-Line Platinum-Doublet Regimens Reasonable in SCLC
Use of platinum-doublet chemotherapy regimen as second-line treatment for patients with relapsed small-cell lung cancer (SCLC) was a reasonable option compared with nonplatinum-based regimens, according to data from a meta-analysis presented at the WCLC Congress 2021. “Optimal second-line chemotherapy for patients with relapsed SCLC remains unclear,” according to study presenter Takashi Sato, MD, PhD, of…